Comprehensive Review of Current and Further Treatment of Cervical Cancer
Authors/Creators
Description
Cervical cancer ranks as the fourth most frequently diagnosed cancer among worldwide and is responsible for more than 300000 deaths each year. Persistent infection with high risk human papilloma virus (HPV) types is the primary cause, with viral oncoproteins E5, E6 and E7 working alongside host cellular factor to initiate and sustain malignant transformation. Although cervical cancer is largely preventable, early detection greatly improves survival outcome. In high income countries where screening and vaccination programs are well established, the disease has become uncommon. In contrast it remains a major cause of mortality in low and middle income nations, where limited health care resources often lead to late stage and non-treatable presentations. Current management strategies include surgery, radiotherapy, chemotherapy, or combination to this. This review outlines the development and progression and cervical cancer and provides and in depth analysis of the strength and limitations of existing treatments. It also highlights emerging therapeutic approaches1. Such as immunotherapy, targeted treatments, combinations regimens, gene based therapies that hold promise for improving patient outcome.